COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt513PMID 24355487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.

  2013cited by this paper
• Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

  2013cited by this paper
• Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.

  2013cited by this paper
• Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer

  2013cited by this paper
• Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis

  2013cited by this paper
• Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.

  2012cited by this paper
• Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.

  2012cited by this paper
• American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

  2012cited by this paper
• Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review.

  2012cited by this paper
• Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

  2012cited by this paper
• Abstract P6-09-08: COMPliance and Arthralgia in Clinical Therapy: The COMPACT trial, assessing the incidence of arthralgia, therapy costs and compliance within the first year of adjuvant anastrozole therapy

  2012cited by this paper
• Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

  2012cited by this paper
• Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

  2011cited by this paper
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

  2011cited by this paper
• Long-term course of pain in breast cancer survivors: a 4-year longitudinal study

  2011cited by this paper
• Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK.

  2011cited by this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2011cited by this paper
• Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

  2010cited by this paper
• Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.

  2010cited by this paper
• Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.

  2008cited by this paper
• Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

  2008cited by this paper
• Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.

  2008cited by this paper
• Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer.

  2008influential reference
• Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

  2008cited by this paper
• Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

  2008cited by this paper
• Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

  2008cited by this paper
• Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy.

  2007cited by this paper
• Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.

  2006cited by this paper
• Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation.

  2005cited by this paper
• Compliance with oral drug therapy in patients with hematologic malignancy.

  1987cited by this paper

• Long-Term Follow-Up Care After Treatment for Primary Breast Cancer: Strategies and Considerations.

  2025cites this paper
• Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes

  2025cites this paper
• Development and Acceptability of a Rebuilding Osteo Strength With Exercise (ROSE) Program for Women With Breast Cancer

  2025cites this paper
• Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib

  2025cites this paper
• A Randomized Controlled Trial of Hypnosis to Manage Musculoskeletal Pain in Breast Cancer Survivors Taking Aromatase Inhibitors.

  2024cites this paper
• Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review

  2023cites this paper
• Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App

  2023cites this paper
• Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

  2023cites this paper
• The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review

  2022cites this paper
• Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

  2022cites this paper
• Pain prevalence and characteristics in survivors of solid cancers: a systematic review and meta-analysis

  2022influential citation
• Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer

  2022cites this paper
• Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

  2022cites this paper
• Psychometric assessment of the Chinese version of the Oxford Knee Score in breast cancer survivors experiencing hormone treatment-related knee dysfunction

  2022cites this paper
• Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

  2022cites this paper
• Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

  2022cites this paper
• Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

  2021cites this paper
• Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis

  2021cites this paper
• Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

  2021cites this paper
• Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis

  2020cites this paper
• Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients

  2020cites this paper
• Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

  2020cites this paper
• Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review

  2020cites this paper
• Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review.

  2019cites this paper
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

  2019cites this paper
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

  2019cites this paper
• Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

  2019influential citation
• Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

  2019cites this paper
• Aromatase inhibitors (AIs) are the standard of care for treatment of both early and advanced hormone-sensitive breast cancer in postmenopausal women. Although AIs

  2018cites this paper
• Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention

  2018cites this paper
• Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

  2018cites this paper
• Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review

  2018cites this paper
• Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

  2018cites this paper
• Update Mammakarzinom 2017 – Etablierung neuer zielgerichteter Therapien

  2018cites this paper
• Adverse effects of adjuvant endocrine therapy

  2018cites this paper
• Побочные эффекты адъювантной гормонотерапии

  2018cites this paper
• Update Mammakarzinom 2018 (Teil 2) – Fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention

  2018cites this paper
• Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

  2017cites this paper
• Breast Cancer Care in the Elderly Patient

  2017cites this paper
• Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

  2017cites this paper
• Update Breast Cancer 2017 – Implementation of Novel Therapies

  2017cites this paper
• Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.

  2017cites this paper
• Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

  2017cites this paper
• Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

  2016cites this paper
• Poor persistence with hormonal therapy among women with breast cancer.

  2016cites this paper
• Toward a Patient-Centered Value Framework in Oncology.

  2016cites this paper
• TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.

  2016cites this paper
• Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study

  2016cites this paper
• Evaluation des Therapiemanagements und der Therapieadhärenz bei postmenopausalen Patientinnen mit hormonrezeptorpositivem Mammakarzinom, die mit Letrozol behandelt werden – die EvaluateTM-Studie

  2015cites this paper
• Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis.

  2015cites this paper
• Adherence to Adjuvant Endocrine Therapy for Breast Cancer: Importance in Women with Low Income

  2015cites this paper
• Safety of aromatase inhibitor therapy in breast cancer

  2015cites this paper
• Breast cancer therapy planning – a novel support concept for a sequential decision making problem

  2015cites this paper
• Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

  2015cites this paper
• Symptoms: Aromatase Inhibitor Induced Arthralgias.

  2015cites this paper
• Postmenopausal breast cancer: a best endocrine strategy?

  2015cites this paper
• Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

  2014cites this paper
• The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.

  2014cites this paper
• Crossover Effects of Estrogen Receptor Status on Breast Cancer-Specific Hazard Rates by Age and Race

  2014cites this paper
• Breast cancer therapy planning – a novel support concept for a sequential decision making problem

  2014cites this paper
• Gelenkschmerzen beeinträchtigen Compliance

  2014cites this paper
• Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider

  2014cites this paper
• Endocrine therapy toxicity: management options.

  2014cites this paper
• Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort

  2013cites this paper